Michael Gelband’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$59.3M Buy
+563,064
New +$52.4M 0.31% 46
2026
Q2
– Sell
-47,750
Closed -$2.69M – 1767
2026
Q1
$2.69M Sell
47,750
-48,568
-50% -$3.16M 0.02% 655
2025
Q4
$7.72M Sell
96,318
-215,533
-69% -$14.5M 0.06% 326
2025
Q3
$15.2M Buy
311,851
+185,336
+146% +$11.5M 0.16% 119
2025
Q2
$9.44M Buy
126,515
+62,174
+97% +$4.12M 0.08% 244
2025
Q1
$4.09M Buy
64,341
+49,898
+345% +$3.39M 0.04% 473
2024
Q4
$1.13M Sell
14,443
-66,500
-82% -$5.34M 0.01% 910
2024
Q3
$6.51M Buy
80,943
+51,667
+176% +$4.17M 0.04% 324
2024
Q2
$2.42M Buy
+29,276
New +$2.58M 0.02% 712
2023
Q3
– Sell
-10,423
Closed -$887K – 1868
2023
Q2
$887K Sell
10,423
-39,809
-79% -$3.37M 0.01% 1148
2023
Q1
$4.16M Buy
50,232
+12,332
+33% +$998K 0.03% 581
2022
Q4
$2.98M Buy
+37,900
New +$3.05M 0.04% 502
2022
Q1
– Sell
-5,726
Closed -$304K – 2368
2021
Q4
$304K Buy
+5,726
New +$349K ﹤0.01% 1653
2021
Q2
– Sell
-6,015
Closed -$668K – 2529
2021
Q1
$668K Sell
6,015
-32,473
-84% -$4.02M 0.01% 1165
2020
Q4
$4.57M Sell
38,488
-14,171
-27% -$1.53M 0.04% 276
2020
Q3
$4.59M Buy
52,659
+14,258
+37% +$1.25M 0.09% 190
2020
Q2
$3.44M Buy
+38,401
New +$3.88M 0.09% 253
2020
Q1
– Sell
-33,437
Closed -$3.84M – 1299
2019
Q4
$3.84M Buy
+33,437
New +$4.05M 0.07% 202

Other funds holding HAE

Michael Gelband's HAE Position: Q3 2026 in Review

Michael Gelband opened a new position in Haemonetics (HAE) in Q3 2026: 563,064 shares worth $59.3M. The stake represents 0.31% of the portfolio and ranks #46 among its holdings. This is a return to the name: Michael Gelband previously reported a position in HAE as recently as Q1 2026.

Michael Gelband first reported a position in HAE in Q4 2019 and has held it in 18 quarters since. 361 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • Michael Gelband held 563,064 shares of Haemonetics worth $59.3M as of Q3 2026.
  • Haemonetics was a new Michael Gelband position in Q3 2026.
  • Haemonetics made up 0.31% of Michael Gelband's portfolio in Q3 2026, its #46 holding.
  • Michael Gelband first reported a position in Haemonetics in Q4 2019 and has held it in 18 quarters since.
  • 361 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.